Holliday cashes in on Glaxo's misery
Wednesday 13 August 1997
Mark Robbins, joint chief executive, said generic companies in the US had been buying in large quantities of ranitidine in readiness for the Glaxo patent expiry in July. Holliday is one of the biggest suppliers of the drug into the US, supplying most of the generic players, including Novopharm, Geneva and Genpharm. "Ranitidine is definitely a boost to us. It is a huge market in the US," he said.
Mr Robbins denied that acourt case brought by Glaxo, which claims Holliday's Spanish subsidiary, Uquifa, is infringing its Zantac patent and could threaten to halt the supply of ranitidine into the US, was an issue.
Mr Robbins said a complex litigation process which resulted in only one generic company, Novopharm, having the right to sell ranitidine until the end of August was benefiting the group, though the outlook depended on how many generics entered the market: "The fewer players there are, the better for us. Generic drugs are price-sensitive. If there are 15 players in the market, the price could fall by 90 per cent."
And why are 'southern' ways of speaking spreading north?
Ten best places to live in the UK: Solihull comes top
Mysterious glowing ‘alien-like creature’ spotted in waters of Bristol Harbour. A jellyfish - or something fishy?
From 'terrorist' to tea with the Queen
UK weather: More surge tides forecast after thousands evacuated along east coast
Nelson Mandela death: his life in pictures
- 1 Cameron's freebie to apartheid South Africa
- 2 Nelson Mandela life story: An unconquerable spirit
- 3 Is this the scariest advert ever? Japanese tyre commercial comes with its own disclaimer and health warning
- 4 A forgotten episode in Russian history leaves links with the Philippines
- 5 From 'terrorist' to tea with the Queen
iJobs Money & Business
£50000 - £65000 per annum + benefits + bonus: Harrington Starr: Market Data SM...
£50000 - £70000 per annum + benefits + bonus: Harrington Starr: Business Analy...
£70000 - £85000 per annum + benefits + bonus: Harrington Starr: Business Analy...
£75000 - £85000 per annum + Bonus and Benefits: Harrington Starr: An award win...